Positive Safety Data from Third Cohort of PI Clinical Trial
Filed with ASX · · 3 pages · English
® ® ® R327 being safe and well tolerated at 500mg IV is a wonderful milestone for the Company. These results are an excellent outcome for this clinically-invasive method of administration, with a few additional participants to strengthen a compelling safety profile, and serves well for regulatory and synergistic program potential.” R327 was indicated to be safe and well tolerated at 500mg with no
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Positive Safety Data from Second Cohort of PI Clinical Trial
- Positive Safety Data from Phase 1 Clinical Trial
- Patients to be Dosed in Ph 1 IV Clinical Trial of R327
- Update on Phase I/II Clinical Trial for Burn Wound Infection
- Appendix 4C and Activity Report
Later from Recce Pharmaceuticals
- Positive Safety Continues in 3rd Cohort PhI Clinical Trial
- S&P DJI Announces March 2022 Quarterly Rebalance
- Safety Committee Clears PhI R327 Dose Increase
- $3.08m R&D Rebate Received
- Positive safety data from 4th Cohort -Phase I Clinical Trial
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals